Author: admin

CAIRO, Nov 23 (Reuters) – Oman signed an agreement with Airbus on Sunday to design, manufacture and launch the sultanate’s first communications satellite, Oman’s state news agency reported.

The new satellite would help boost Oman’s communications system and build capacities in areas of space and future technologies, the state news agency said.

Sign up here.

Our Standards: The Thomson Reuters Trust Principles., opens new tab

• Earlier this week, Raymond James upgraded its rating on Doximity, emphasizing improved long-term growth potential and opportunities tied to artificial intelligence capabilities.

• The analyst cited that Doximity’s recent focus on AI monetization and durable gains in market share could strengthen future revenue streams and company positioning.

• Let’s explore how the emphasis on AI-driven monetization may reshape Doximity’s investment narrative and its outlook going forward.

Find companies with promising cash flow potential yet trading below their fair value.

To be a Doximity shareholder, you need to believe that its transition toward AI-powered healthcare workflow tools can unlock greater platform stickiness, deeper client relationships, and ultimately a durable source of growth and margin expansion. The recent Raymond James upgrade underscores renewed confidence in AI monetization, but it does not fundamentally change the key near-term catalyst: evidence of material revenue contribution from new AI features. The biggest current risk, ongoing reliance on pharmaceutical marketing budgets and potential regulatory pressures, remains largely unchanged by this news.

Looking at the most recent Q2 FY2026 earnings report, Doximity posted meaningful year-over-year increases in both revenue and net income. While these results show continued business momentum, it’s too soon to see direct financial impact from newer AI-driven initiatives discussed in the Raymond James analysis. With AI monetization still an emerging factor, near-term expectations are best managed around core revenue streams and market share retention rather than immediate windfalls from new technology.

However, in contrast to these positive signals around platform growth, investors should also keep in mind …

Read the full narrative on Doximity (it’s free!)

Doximity’s outlook anticipates $805.8 million in revenue and $280.5 million in earnings by 2028. This is based on analysts’ assumptions of 11.0% annual revenue growth and a $45.4 million earnings increase from the current earnings of $235.1 million.

Uncover how Doximity’s forecasts yield a $71.11 fair value, a 41% upside to its current price.

Eight members of the Simply Wall St Community have fair value estimates for Doximity ranging from US$32.58 up to US$78.58. While some focus on expanding AI integration as a growth catalyst, others see substantial risk in the company’s exposure to pharmaceutical marketing cycles, reminding you to explore multiple viewpoints when forming expectations about future performance.

Explore 8 other fair value estimates on Doximity – why the stock might be worth as much as 56% more than the current price!

Disagree with existing narratives? Create your own in under 3 minutes – extraordinary investment returns rarely come from following the herd.

• A great starting point for your Doximity research is our analysis highlighting 4 key rewards that could impact your investment decision.

• Our free Doximity research report provides a comprehensive fundamental analysis summarized in a single visual – the Snowflake – making it easy to evaluate Doximity’s overall financial health at a glance.

Don’t miss your shot at the next 10-bagger. Our latest stock picks just dropped:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include DOCS.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com